Loading...

Table of Content

    01 January 2020, Volume 15 Issue on line Previous Issue    Next Issue
    For Selected: Toggle Thumbnails
    The effect of ISP and PAP4 peptides treatment on the functional motor recovery in rat following spinal ventral root injury
    Shiqin Lv , Wutian Wu
    2020, 15 (on line):  1-8. 
    Abstract ( 76 )   PDF (3311KB) ( 298 )   Save
    Spinal ventral root injury leads to significant loss of motor function due to the inefficient
    axon regeneration and severe atrophy of target muscle. Pharmacological methods present
    a valuable and clinically feasible strategy for promoting regeneration following injury. Here,
    we propose two small peptides, ISP and PAP4, which promote regeneration by inhibiting
    chondroitin sulfate proteoglycans (CSPG) and phosphatase and tensin homolog (PTEN),
    respectively. CSPGs, the dominant suppressors of axonal regeneration in scar tissue,
    exert an inhibitory effect via neuronal receptors such as protein tyrosine phosphatase-σ
    (PTPσ). It has previously been verified that ISP can modulate PTPσ to reduce the inhibitory
    effect of CSPGs. It is well established that PI3K/AKT signaling pathway exerts a positive
    role in axon regeneration. Conversely, PTEN acts as a negative regulator of this pathway,
    inhibiting the regeneration of axons. PTEN antagonist peptides (in particular PAP4) can
    promote descending serotonergic fibers growth and corticospinal fiber sprouting in the
    rostral spinal cord following SCI. In this study, we demonstrate that ISP and PAP treatment
    can remarkably improve motor function recovery following a spinal ventral root crush
    surgery. Peptide-treated animals showed increased motoneuron survival, a greater number
    of regenerated axons, healthier neuromuscular junctions and enhanced potentiated
    electrical responses in motor units. Our study suggests that ISP and PAP4 present a novel
    pharmacological method for accelerating motor functional recovery after peripheral nerve
    injury.
    Related Articles | Metrics